Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Opioid-Induced Constipation market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Opioid-Induced Constipation market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Opioid-Induced Constipation market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Opioid-Induced Constipation products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Opioid-Induced Constipation products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Opioid-Induced Constipation market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Opioid-Induced Constipation development has been the leading industry trend of Opioid-Induced Constipation market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Opioid-Induced Constipation Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Methylnaltrexone Bromide,Lubiprostone,Naloxegol,Others |
| By Application Outlook |
Hospital,Pharmacy, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Takeda Pharmaceuticals,Bayer,Sanofi,Mallinckrodt,Salix (Bausch Health),AstraZeneca,Progenics Pharmaceuticals,Purdue Pharm,Nektar Therapeutics,Daiichi Sankyo,Prestige,GSK,Shionogi |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Takeda Pharmaceuticals
- Bayer
- Sanofi
- Mallinckrodt
- Salix (Bausch Health)
- AstraZeneca
- Progenics Pharmaceuticals
- Purdue Pharm
- Nektar Therapeutics
- Daiichi Sankyo
- Prestige
- GSK
- Shionogi
Opioid-Induced Constipation Market, By Type
- Methylnaltrexone Bromide
- Lubiprostone
- Naloxegol
- Others
Opioid-Induced Constipation Market, By Application
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global Opioid-Induced Constipation Market Report 2020, Forecast to 2027
1 Scope of the Study
1.1 Opioid-Induced Constipation Introduction
1.2 Research Programs
1.3 Analysis of Macroeconomic Indicators
1.4 Years Considered
1.5 Methodology
1.6 Data Source
1.7 Research Objectives
2 Opioid-Induced Constipation Industry Overview
2.1 Global Opioid-Induced Constipation Market Size (Million USD) Comparison by Regions (2020-2027)
2.1.1 Opioid-Induced Constipation Global Import Market Analysis
2.1.2 Opioid-Induced Constipation Global Export Market Analysis
2.1.3 Opioid-Induced Constipation Global Main Region Market Analysis
2.2 Market Analysis by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3.2 Pharmacy
2.4.2 Global Opioid-Induced Constipation Revenue and Market Share by Manufacturer (2018-2020)
2.4.3 Global Opioid-Induced Constipation Industry Concentration Ratio (CR5 and HHI)
2.4.4 Top 5 Opioid-Induced Constipation Manufacturer Market Share
2.4.5 Top 10 Opioid-Induced Constipation Manufacturer Market Share
2.4.6 Date of Key Manufacturers Enter into Opioid-Induced Constipation Market
2.4.7 Key Manufacturers Opioid-Induced Constipation Product Offered
2.4.8 Mergers & Acquisitions Planning
2.5 Opioid-Induced Constipation Historical Development Overview
2.6 Market Dynamics
2.6.1 Market Opportunities
2.6.2 Market Risk
2.6.3 Market Driving Force
2.6.4 Porter's Five Forces Analysis
3 Upstream and Downstream Market Analysis
3.1 Upstream Analysis
3.1.1 Macro Analysis of Upstream Markets
3.1.2 Key Players in Upstream Markets
3.1.3 Upstream Market Trend Analysis
3.1.4 Opioid-Induced Constipation Manufacturing Cost Analysis
3.2 Downstream Market Analysis
3.2.1 Macro Analysis of Down Markets
3.2.2 Key Players in Down Markets
3.2.3 Downstream Market Trend Analysis
3.2.4 Sales Channel, Distributors, Traders and Dealers
4 Global Opioid-Induced Constipation Market Size Categorized by Regions
4.1 Global Opioid-Induced Constipation Revenue, Sales and Market Share by Regions
4.1.1 Global Opioid-Induced Constipation Sales and Market Share by Regions (2015-2020)
4.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Regions (2015-2020)
4.2 Europe Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.3 APAC Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.4 North America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.5 South America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.6 Middle East & Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5 Europe Opioid-Induced Constipation Market Size Categorized by Countries
5.1 Europe Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
5.1.1 Europe Opioid-Induced Constipation Sales by Countries (2015-2020)
5.1.2 Europe Opioid-Induced Constipation Revenue by Countries (2015-2020)
5.1.3 Germany Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.1.4 UK Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.1.5 France Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.1.6 Russia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.1.7 Italy Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.1.8 Spain Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.2 Europe Opioid-Induced Constipation Revenue (Value) by Manufacturers (2018-2020)
5.3 Europe Opioid-Induced Constipation Sales, Revenue and Market Share by Type (2015-2020)
5.3.1 Europe Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
5.3.2 Europe Opioid-Induced Constipation Revenue and Revenue Share by Type (2015-2020)
5.4 Europe Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
6 Asia-Pacific Opioid-Induced Constipation Market Size Categorized by Countries
6.1 Asia-Pacific Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
6.1.1 Asia-Pacific Opioid-Induced Constipation Sales by Countries (2015-2020)
6.1.2 Asia-Pacific Opioid-Induced Constipation Revenue by Countries (2015-2020)
6.1.3 China Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.1.4 Japan Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.1.5 Korea Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.1.6 India Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.1.7 Southeast Asia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.1.8 Australia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.2 Asia-Pacific Opioid-Induced Constipation Sales and Revenue (Value) by Manufacturers (2018-2020)
6.3 Asia-Pacific Opioid-Induced Constipation Sales, Revenue and Market Share by Type (2015-2020)
6.3.1 Asia-Pacific Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
6.3.2 Asia-Pacific Opioid-Induced Constipation Revenue and Revenue Share by Type (2015-2020)
6.4 Asia-Pacific Opioid-Induced Constipation Sales and Market Share by Application (2015-2020)
7 North America Opioid-Induced Constipation Market Size Categorized by Countries
7.1 North America Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
7.1.1 North America Opioid-Induced Constipation Sales by Countries (2015-2020)
7.1.2 North America Opioid-Induced Constipation Revenue by Countries (2015-2020)
7.1.3 United States Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.1.4 Canada Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.1.5 Mexico Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.2 North America Opioid-Induced Constipation Revenue (Value) by Manufacturers (2018-2020)
7.3 North America Opioid-Induced Constipation Sales, Revenue and Market Share by Type (2015-2020)
7.3.1 North America Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
7.3.2 North America Opioid-Induced Constipation Revenue and Revenue Share by Type (2015-2020)
7.4 North America Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
8 South America Opioid-Induced Constipation Market Size Categorized by Countries
8.1 South America Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
8.1.1 South America Opioid-Induced Constipation Sales by Countries (2015-2020)
8.1.2 South America Opioid-Induced Constipation Revenue by Countries (2015-2020)
8.1.3 Brazil Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
8.2 South America Opioid-Induced Constipation Revenue (Value) by Manufacturers (2018-2020)
8.3 South America Opioid-Induced Constipation Sales, Revenue and Market Share by Type (2015-2020)
8.3.1 South America Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
8.3.2 South America Opioid-Induced Constipation Revenue and Revenue Share by Type (2015-2020)
8.4 South America Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
9 Middle East and Africa Opioid-Induced Constipation Market Size Categorized by Countries
9.1 Middle East and Africa Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Countries (2015-2020)
9.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Countries (2015-2020)
9.1.3 GCC Countries Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.1.4 Turkey Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.1.5 Egypt Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.1.6 South Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.2 Middle East and Africa Opioid-Induced Constipation Revenue (Value) by Manufacturers (2018-2020)
9.3 Middle East and Africa Opioid-Induced Constipation Sales, Revenue and Market Share by Type
9.3.1 Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
9.3.2 Middle East and Africa Opioid-Induced Constipation Revenue and Revenue Share by Type (2015-2020)
9.4 Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
10 Global Opioid-Induced Constipation Market Segment by Type
10.1 Global Opioid-Induced Constipation Revenue, Sales and Market Share by Type (2015-2020)
10.1.1 Global Opioid-Induced Constipation Sales and Market Share by Type (2015-2020)
10.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2015-2020)
10.2 Methylnaltrexone Bromide Sales Growth Rate and Price
10.2.1 Global Methylnaltrexone Bromide Sales Growth Rate (2015-2020)
10.2.2 Global Methylnaltrexone Bromide Price (2015-2020)
10.3 Lubiprostone Sales Growth Rate and Price
10.3.1 Global Lubiprostone Sales Growth Rate (2015-2020)
10.3.2 Global Lubiprostone Price (2015-2020)
10.4 Naloxegol Sales Growth Rate and Price
10.4.1 Global Naloxegol Sales Growth Rate (2015-2020)
10.4.2 Global Naloxegol Price (2015-2020)
10.5 Others Sales Growth Rate and Price
10.5.1 Global Others Sales Growth Rate (2015-2020)
10.5.2 Global Others Price (2015-2020)
11.1 Global Opioid-Induced ConstipationSales Market Share by Application (2015-2020)
11.2 Hospital Sales Growth Rate (2015-2020)
11.3 Pharmacy Sales Growth Rate (2015-2020)
12.1 Global Opioid-Induced Constipation Revenue, Sales and Growth Rate (2020-2027)
12.2 Opioid-Induced Constipation Market Forecast by Regions (2020-2027)
12.2.1 Europe Opioid-Induced Constipation Market Forecast (2020-2027)
12.2.2 APAC Opioid-Induced Constipation Market Forecast (2020-2027)
12.2.3 North America Opioid-Induced Constipation Market Forecast (2020-2027)
12.2.4 South America Opioid-Induced Constipation Market Forecast (2020-2027)
12.2.5 Middle East & Africa Opioid-Induced Constipation Market Forecast (2020-2027)
12.3 Opioid-Induced Constipation Market Forecast by Type (2020-2027)
12.3.1 Global Opioid-Induced Constipation Sales Forecast by Type (2020-2027)
12.3.2 Global Opioid-Induced Constipation Market Share Forecast by Type (2020-2027)
12.4 Opioid-Induced Constipation Market Forecast by Application (2020-2027)
12.4.1 Global Opioid-Induced Constipation Sales Forecast by Application (2020-2027)
12.4.2 Global Opioid-Induced Constipation Market Share Forecast by Application (2020-2027)
13 Analysis of Opioid-Induced Constipation Industry Key Manufacturers
13.1 Takeda Pharmaceuticals
13.1.1 Company Details
13.1.2 Product Information
13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.1.4 Main Business Overview
13.1.5 Takeda Pharmaceuticals News
13.2 Bayer
13.2.1 Company Details
13.2.2 Product Information
13.2.3 Bayer Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.2.4 Main Business Overview
13.2.5 Bayer News
13.3 Sanofi
13.3.1 Company Details
13.3.2 Product Information
13.3.3 Sanofi Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.3.4 Main Business Overview
13.3.5 Sanofi News
13.4 Mallinckrodt
13.4.1 Company Details
13.4.2 Product Information
13.4.3 Mallinckrodt Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.4.4 Main Business Overview
13.4.5 Mallinckrodt News
13.5 Salix (Bausch Health)
13.5.1 Company Details
13.5.2 Product Information
13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.5.4 Main Business Overview
13.5.5 Salix (Bausch Health) News
13.6 AstraZeneca
13.6.1 Company Details
13.6.2 Product Information
13.6.3 AstraZeneca Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.6.4 Main Business Overview
13.6.5 AstraZeneca News
13.7 Progenics Pharmaceuticals
13.7.1 Company Details
13.7.2 Product Information
13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.7.4 Main Business Overview
13.7.5 Progenics Pharmaceuticals News
13.8 Purdue Pharm
13.8.1 Company Details
13.8.2 Product Information
13.8.3 Purdue Pharm Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.8.4 Main Business Overview
13.8.5 Purdue Pharm News
13.9 Nektar Therapeutics
13.9.1 Company Details
13.9.2 Product Information
13.9.3 Nektar Therapeutics Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.9.4 Main Business Overview
13.9.5 Nektar Therapeutics News
13.10 Daiichi Sankyo
13.10.1 Company Details
13.10.2 Product Information
13.10.3 Daiichi Sankyo Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.10.4 Main Business Overview
13.10.5 Daiichi Sankyo News
13.11 Prestige
13.11.1 Company Details
13.11.2 Product Information
13.11.3 Prestige Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.11.4 Main Business Overview
13.11.5 Prestige News
13.12 GSK
13.12.1 Company Details
13.12.2 Product Information
13.12.3 GSK Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.12.4 Main Business Overview
13.12.5 GSK News
13.13 Shionogi
13.13.1 Company Details
13.13.2 Product Information
13.13.3 Shionogi Opioid-Induced Constipation Production, Price, Cost, Gross Margin, and Revenue (2018-2020)
13.13.4 Main Business Overview
13.13.5 Shionogi News
15 Appendix
